Cambridge Trust’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $7.12M | Sell |
131,329
-226,978
| -63% | -$11.6M | 0.27% | 81 |
|
|
2023
Q4 | $18.4M | Sell |
358,307
-84,966
| -19% | -$4.46M | 0.77% | 39 |
|
|
2023
Q3 | $25.7M | Sell |
443,273
-58,581
| -12% | -$3.59M | 1.19% | 26 |
|
|
2023
Q2 | $32.1M | Sell |
501,854
-19,015
| -4% | -$1.28M | 1.45% | 21 |
|
|
2023
Q1 | $36.1M | Buy |
520,869
+44,103
| +9% | +$3.11M | 1.72% | 14 |
|
|
2022
Q4 | $34.3M | Buy |
476,766
+53,042
| +13% | +$4M | 1.53% | 20 |
|
|
2022
Q3 | $30.1M | Buy |
423,724
+3,767
| +0.9% | +$273K | 1.43% | 20 |
|
|
2022
Q2 | $32.3M | Buy |
419,957
+47,410
| +13% | +$3.61M | 1.42% | 18 |
|
|
2022
Q1 | $27.2M | Buy |
372,547
+9,392
| +3% | +$631K | 0.95% | 33 |
|
|
2021
Q4 | $22.6M | Buy |
363,155
+12,723
| +4% | +$746K | 0.73% | 51 |
|
|
2021
Q3 | $20.7M | Buy |
350,432
+21,627
| +7% | +$1.42M | 0.78% | 48 |
|
|
2021
Q2 | $22M | Sell |
328,805
-1,616
| -0.5% | -$105K | 0.83% | 45 |
|
|
2021
Q1 | $20.9M | Buy |
330,421
+8,980
| +3% | +$559K | 0.85% | 44 |
|
|
2020
Q4 | $19.9M | Buy |
321,441
+26,929
| +9% | +$1.66M | 0.95% | 43 |
|
|
2020
Q3 | $17.8M | Buy |
294,512
+22
| +0% | +$1.32K | 0.92% | 41 |
|
|
2020
Q2 | $17.5M | Sell |
294,490
-18,948
| -6% | -$1.13M | 0.92% | 40 |
|
|
2020
Q1 | $17.5M | Buy |
313,438
+11,583
| +4% | +$708K | 1.2% | 33 |
|
|
2019
Q4 | $19.4M | Buy |
301,855
+158,911
| +111% | +$9.1M | 1.02% | 35 |
|
|
2019
Q3 | $7.25M | Buy |
142,944
+110,305
| +338% | +$5.18M | 0.42% | 72 |
|
|
2019
Q2 | $1.48M | Sell |
32,639
-4,052
| -11% | -$189K | 0.09% | 110 |
|
|
2019
Q1 | $1.75M | Sell |
36,691
-1,560
| -4% | -$77.7K | 0.1% | 104 |
|
|
2018
Q4 | $1.99M | Sell |
38,251
-1,765
| -4% | -$94.8K | 0.14% | 95 |
|
|
2018
Q3 | $2.48M | Sell |
40,016
-25
| -0.1% | -$1.48K | 0.14% | 92 |
|
|
2018
Q2 | $2.22M | Sell |
40,041
-133
| -0.3% | -$7.18K | 0.14% | 95 |
|
|
2018
Q1 | $2.54M | Buy |
40,174
+1,275
| +3% | +$82K | 0.16% | 95 |
|
|
2017
Q4 | $2.38M | Hold |
38,899
| – | – | 0.15% | 97 |
|
|
2017
Q3 | $2.48M | Sell |
38,899
-384
| -1% | -$22.4K | 0.17% | 94 |
|
|
2017
Q2 | $2.19M | Sell |
39,283
-1,275
| -3% | -$69.4K | 0.15% | 97 |
|
|
2017
Q1 | $2.21M | Sell |
40,558
-215
| -0.5% | -$11.8K | 0.15% | 102 |
|
|
2016
Q4 | $2.38M | Sell |
40,773
-887
| -2% | -$48.5K | 0.17% | 98 |
|
|
2016
Q3 | $2.25M | Sell |
41,660
-3,602
| -8% | -$231K | 0.16% | 100 |
|
|
2016
Q2 | $3.33M | Sell |
45,262
-850
| -2% | -$60.1K | 0.25% | 86 |
|
|
2016
Q1 | $2.94M | Sell |
46,112
-427
| -0.9% | -$26.9K | 0.24% | 83 |
|
|
2015
Q4 | $3.2M | Sell |
46,539
-392
| -0.8% | -$25.9K | 0.26% | 79 |
|
|
2015
Q3 | $2.78M | Sell |
46,931
-450
| -0.9% | -$28.5K | 0.24% | 84 |
|
|
2015
Q2 | $3.15M | Sell |
47,381
-3,045
| -6% | -$201K | 0.26% | 81 |
|
|
2015
Q1 | $3.25M | Buy |
50,426
+4,745
| +10% | +$297K | 0.27% | 82 |
|
|
2014
Q4 | $2.7M | Sell |
45,681
-3,912
| -8% | -$221K | 0.23% | 82 |
|
|
2014
Q3 | $2.54M | Sell |
49,593
-3,273
| -6% | -$163K | 0.23% | 80 |
|
|
2014
Q2 | $2.56M | Buy |
52,866
+2,436
| +5% | +$120K | 0.22% | 80 |
|
|
2014
Q1 | $2.62M | Sell |
50,430
-523
| -1% | -$27.8K | 0.24% | 80 |
|
|
2013
Q4 | $2.71M | Sell |
50,953
-3,150
| -6% | -$160K | 0.25% | 78 |
|
|
2013
Q3 | $2.5M | Buy |
54,103
+300
| +0.6% | +$13.2K | 0.25% | 77 |
|
|
2013
Q2 | $2.4M | Buy |
+53,803
| New | +$2.34M | 0.25% | 72 |
|
Other funds holding BMY
Cambridge Trust's BMY Position: Q1 2024 in Review
Cambridge Trust reduced its Bristol-Myers Squibb (BMY) stake by 63% in Q1 2024, selling an estimated $11.6M and leaving 131,329 shares worth $7.12M. The position accounts for 0.27% of the portfolio, ranked #81.
Cambridge Trust first reported a position in BMY in Q2 2013 and has held it in 44 quarters since. The position peaked at $36.1M in Q1 2023. 2,332 funds tracked by Wall St. Rank hold BMY as of Q1 2024.
- Cambridge Trust held 131,329 shares of Bristol-Myers Squibb worth $7.12M as of Q1 2024.
- Cambridge Trust sold 226,978 Bristol-Myers Squibb shares in Q1 2024, an estimated $11.6M.
- Bristol-Myers Squibb made up 0.27% of Cambridge Trust's portfolio in Q1 2024, its #81 holding.
- Cambridge Trust first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 44 quarters since.
- Cambridge Trust's Bristol-Myers Squibb position peaked at $36.1M in Q1 2023.
- 2,332 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2024.
Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.